PE20150645A1 - Proteinas de fusion de interleuquina 10 y usos de las mismas - Google Patents

Proteinas de fusion de interleuquina 10 y usos de las mismas

Info

Publication number
PE20150645A1
PE20150645A1 PE2015000169A PE2015000169A PE20150645A1 PE 20150645 A1 PE20150645 A1 PE 20150645A1 PE 2015000169 A PE2015000169 A PE 2015000169A PE 2015000169 A PE2015000169 A PE 2015000169A PE 20150645 A1 PE20150645 A1 PE 20150645A1
Authority
PE
Peru
Prior art keywords
fusion proteins
interleuquin
methods
relates
polynucleotides
Prior art date
Application number
PE2015000169A
Other languages
English (en)
Inventor
Lydia Jasmin Duerner
Thomas Emrich
Jens Fischer
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Daigen Xu
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of PE20150645A1 publication Critical patent/PE20150645A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere de manera general a proteinas de fusion de anticuerpos e interleuquina-10 (IL-10). Ademas, la invencion se refiere a polinucleotidos codificantes de dichas proteinas de fusion y a vectores y celulas huesped que comprenden dichos polinucleotidos. La invencion se refiere ademas a metodos para producir las proteinas de fusion de la invencion y a metodos de utilizacion de las mismas en el tratamiento de enfermedades
PE2015000169A 2012-08-08 2013-08-05 Proteinas de fusion de interleuquina 10 y usos de las mismas PE20150645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12179709 2012-08-08

Publications (1)

Publication Number Publication Date
PE20150645A1 true PE20150645A1 (es) 2015-05-11

Family

ID=48917543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000169A PE20150645A1 (es) 2012-08-08 2013-08-05 Proteinas de fusion de interleuquina 10 y usos de las mismas

Country Status (23)

Country Link
US (2) US9346872B2 (es)
EP (1) EP2882774B1 (es)
JP (3) JP2015530983A (es)
KR (1) KR20150038012A (es)
CN (1) CN104540848B (es)
AR (1) AR092050A1 (es)
AU (1) AU2013301656A1 (es)
BR (1) BR112015002085A2 (es)
CA (1) CA2876285A1 (es)
CL (1) CL2014003605A1 (es)
CO (1) CO7151522A2 (es)
CR (1) CR20140565A (es)
EA (1) EA201500208A1 (es)
HK (1) HK1209439A1 (es)
IL (1) IL236809A0 (es)
MA (1) MA20150232A1 (es)
MX (1) MX2015001675A (es)
PE (1) PE20150645A1 (es)
PH (1) PH12015500284A1 (es)
SG (1) SG11201408526SA (es)
TW (1) TW201418283A (es)
WO (1) WO2014023673A1 (es)
ZA (1) ZA201409304B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
KR101852245B1 (ko) 2011-02-10 2018-04-25 로슈 글리카트 아게 돌연변이 인터루킨-2 폴리펩티드
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
KR20160083884A (ko) 2013-11-01 2016-07-12 스페리움 바이오메드 에스.엘. 치료제 및 미용제의 경피 전달을 위한 봉입체
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
JP6836500B2 (ja) 2014-05-16 2021-03-03 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 自己免疫状態および炎症状態を治療するための方法および組成物
EP3174894B1 (en) 2014-07-30 2021-06-23 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN108064237B (zh) 2014-11-14 2022-02-11 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体的抗原结合分子
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
EP3973980A1 (en) 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
US11219645B2 (en) 2015-11-18 2022-01-11 Duke University Tumor infiltrating lymphocytes for treatment of cancer
PE20181358A1 (es) * 2015-12-04 2018-08-22 Novartis Ag Composiciones de anticuerpo injertado con citoquina y metodos para su uso en inmunorregulacion
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
CA3016035A1 (en) 2016-03-31 2017-10-05 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10
CN108948207B (zh) * 2017-05-22 2020-11-13 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
EP3688023A4 (en) * 2017-09-25 2021-06-30 Dingfu Biotarget Co., Ltd PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
WO2019057180A1 (en) * 2017-09-25 2019-03-28 Dingfu Biotarget Co., Ltd. PROTEIN HETÉRODIMÈRE AND USE THEREOF
WO2020047462A2 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
CN113365663A (zh) 2018-08-30 2021-09-07 Hcw生物科技公司 单链嵌合多肽和其用途
WO2020108426A1 (zh) * 2018-11-26 2020-06-04 江苏恒瑞医药股份有限公司 一种人白细胞介素10变体及其衍生物
US11084857B2 (en) 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
WO2020160244A1 (en) * 2019-02-01 2020-08-06 Uab Research Foundation Methods and compositions for il10 signaling antagonism
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
KR20210139312A (ko) 2019-03-06 2021-11-22 데카 바이오사이언시즈, 인크. Il-10 변이체 분자, 및 염증 질환 및 종양학의 치료 방법
CN111909276A (zh) * 2019-05-10 2020-11-10 复旦大学 一种融合蛋白及其用途
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
KR20220035394A (ko) 2019-06-21 2022-03-22 에이치씨더블유 바이올로직스, 인크. 다중-사슬 키메라 폴리펩티드 및 이의 용도
EP3998282A4 (en) * 2019-07-08 2023-08-09 Progen Co., Ltd. NEW FUSION PROTEIN AND ITS USE
KR20210006300A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 알러지 질환 치료용 약학적 조성물
JP7497417B2 (ja) * 2019-07-08 2024-06-10 プロジェン・カンパニー・リミテッド 新規ｉｌ－１０変異体タンパク質及びその用途
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
BR112022009938A2 (pt) 2019-11-25 2022-09-13 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
IL295077A (en) 2020-02-11 2022-09-01 Hcw Biologics Inc Methods for treating age-related and inflammatory diseases
JP2023519106A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド クロマトグラフィー樹脂およびその使用
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
WO2021230705A1 (ko) * 2020-05-14 2021-11-18 주식회사 프로젠 신규 재조합 융합단백질 및 그의 용도
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
JP2023527869A (ja) 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
AU2020459746A1 (en) * 2020-07-20 2023-03-16 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising IL-10
US20230279092A1 (en) * 2020-07-20 2023-09-07 Viela Bio, Inc. Immunocytokines for treatment of autoimmune and inflammatory conditions
WO2022124950A1 (en) * 2020-12-10 2022-06-16 Joint Stock Company "Biocad" Immunocytokine for activating human il-10ra receptor and use thereof
KR20220099656A (ko) * 2021-01-07 2022-07-14 주식회사 프로젠 신규 il-10 변이체 융합단백질 생산용 세포주 및 그의 용도
US20240076331A1 (en) * 2021-02-01 2024-03-07 AskGene Pharma, Inc. Chimeric Molecules Comprising an IL-10 or TGF-Beta Agonist Polypeptide
CN116063570A (zh) * 2021-11-02 2023-05-05 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
AU2023228683A1 (en) 2022-03-02 2024-09-19 Immunitybio, Inc. Method of treating pancreatic cancer
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1096187A (en) 1977-04-18 1981-02-24 Souhei Monden Ornament adapted to be fixed by permanent magnets
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
ES2530340T3 (es) 2004-07-15 2015-03-02 Xencor Inc Variantes de Fc optimizadas
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2648484A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
DK2209805T3 (en) * 2007-10-30 2017-10-16 Philogen Spa Antigen associated with rheumatoid arthritis
EP2310417A4 (en) * 2008-07-11 2012-01-11 Forskarpatent I Syd Ab FOR OXIDIZED LDL SPECIFIC ANTIBODY FUSION AND CONJUGATED PROTEINS
AR077879A1 (es) 2009-08-17 2011-09-28 Roche Glycart Ag Inmunoconjugados dirigidos
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
CN103476795B (zh) 2011-03-29 2016-07-06 罗切格利卡特公司 抗体Fc变体
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão

Also Published As

Publication number Publication date
US20140044674A1 (en) 2014-02-13
JP2019033755A (ja) 2019-03-07
ZA201409304B (en) 2017-09-27
MA20150232A1 (fr) 2015-07-31
US20160340413A1 (en) 2016-11-24
JP2015530983A (ja) 2015-10-29
EA201500208A1 (ru) 2015-07-30
CO7151522A2 (es) 2014-12-29
SG11201408526SA (en) 2015-03-30
EP2882774A1 (en) 2015-06-17
HK1209439A1 (en) 2016-04-01
BR112015002085A2 (pt) 2017-12-19
WO2014023673A1 (en) 2014-02-13
IL236809A0 (en) 2015-03-31
MX2015001675A (es) 2015-04-10
JP6985232B2 (ja) 2021-12-22
CN104540848A (zh) 2015-04-22
CR20140565A (es) 2015-02-12
CN104540848B (zh) 2019-05-31
CL2014003605A1 (es) 2015-04-06
EP2882774B1 (en) 2018-10-03
JP2021087426A (ja) 2021-06-10
TW201418283A (zh) 2014-05-16
AR092050A1 (es) 2015-03-18
US9346872B2 (en) 2016-05-24
CA2876285A1 (en) 2014-02-13
AU2013301656A1 (en) 2015-01-15
KR20150038012A (ko) 2015-04-08
US10040843B2 (en) 2018-08-07
PH12015500284A1 (en) 2015-04-27

Similar Documents

Publication Publication Date Title
PE20150645A1 (es) Proteinas de fusion de interleuquina 10 y usos de las mismas
PE20150752A1 (es) Proteinas de fusion de interleuquina-2 y usos de las mismas
AR113177A2 (es) Polipéptidos que tienen actividad de lisozima y polinucleótidos que los codifican
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
AR122864A2 (es) Variantes de lipasa y polinucleótidos que las codifican
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
CR20170203A (es) Moleculas de unión a antígeno biespecíficas activadoras de células t
PE20151410A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
CR20150258A (es) Anticuerpos anti-ceacam5 y usos de éstos
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
TN2014000438A1 (en) Anti-fcrn antibodies
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
CL2014000134A1 (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.
AR073088A1 (es) Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos
BR112017013956A2 (pt) proteínas de fusão de citocinas
BR112017023131A2 (pt) anticorpos anti- fcrn
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
BR112015021681A2 (pt) proteínas de ligação para pcsk9
PH12016500753B1 (en) Antibodies specific to fcrn
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
BR112016013371A2 (pt) melhorias em proteína de fusão pesticida
TH176916A (th) แอนติ-FcRn แอนติบอดี
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения

Legal Events

Date Code Title Description
FD Application declared void or lapsed